What is a mineralocorticoid receptor antagonist and how does finerenone work?

Mineralocorticoid receptors, when activated by aldosterone, drive inflammation and fibrosis in kidney and heart tissue — mechanisms that accelerate both CKD progression and cardiovascular disease. Finerenone selectively blocks these receptors, reducing that inflammatory and fibrotic signalling. Unlike older drugs in this class (spironolactone, eplerenone), finerenone is more selective for the kidney, which reduces the risk of hyperkalaemia (high potassium) that limited older drugs' usefulness at therapeutic doses.

Should I ask my GP for finerenone if I have CKD but not diabetes?

Australian clinical guidelines for non-diabetic CKD have not yet incorporated the new trial evidence — guideline updates typically take one to two years after landmark publications. Rather than asking for a specific drug, the more useful question at your next GP visit is: 'Are my medicines optimised for both kidney protection and cardiovascular risk?' Your GP will know the current evidence and can advise on what is appropriate for your clinical picture. The most important first step if you haven't had kidney function checked recently is to ask for a urine albumin:creatinine ratio and eGFR.

Finerenone's kidney benefit confirmed beyond diabetes: three major trials

What just happened

Three major clinical trials have simultaneously expanded the evidence base for finerenone, a mineralocorticoid receptor antagonist, in chronic kidney disease (CKD). Published in The New England Journal of Medicine, JAMA, and The Lancet, and reported by the George Institute for Global Health — Australia’s leading global health research institution — the trials collectively demonstrate that finerenone’s clinical benefit extends well beyond diabetic CKD.

The headline result from a pooled analysis of 14,574 patients: a 24% reduction in the risk of kidney failure or progression, a 20% reduction in heart failure hospitalisation or cardiovascular death, and a 12% reduction in all-cause mortality.

These are large effect sizes across a large, heterogeneous population in well-designed trials in the highest-tier peer-reviewed journals. This is not preliminary signal. It is the kind of convergent evidence that drives guideline change.

The both-and

The evidence for finerenone’s expanded benefit is now substantial and published at the highest level of the evidence hierarchy. The complication is that Australian guideline incorporation and clinical access will take time — which is the appropriate and normal course of drug development, and it matters to understand why that lag exists.

What the three trials showed

The FIND-CKD trial, published in The New England Journal of Medicine, enrolled patients with non-diabetic CKD — the population for whom finerenone was not previously indicated. The results showed a 23% reduced risk of kidney failure, disease progression, heart failure, or cardiovascular death.

A separate publication in JAMA focused specifically on glomerular disease — a heterogeneous group of kidney conditions frequently seen in younger patients, including women in their reproductive years, and one of the more difficult subsets to manage clinically. Finerenone showed a 26% risk reduction for kidney failure or CKD progression, and a 42% reduction in albuminuria at 12 months. Albuminuria — protein in the urine — is both a direct marker of kidney damage and an independent cardiovascular risk factor. A 42% reduction is clinically meaningful.

The Lancet INFINITY analysis pooled the full dataset: 14,574 patients with both diabetic and non-diabetic CKD. This synthetic analysis across the full population provides the powered, heterogeneous evidence that guideline bodies require before incorporating a new indication. It is the final piece in the standard pathway from landmark trial to clinical practice change.

What CKD means for women specifically

Kidney Health Australia estimates that CKD affects approximately 1 in 10 Australians — with the majority undiagnosed. Women face particular risk from two directions. Hypertension, which is the second most common cause of CKD in Australia, is systematically underdiagnosed in women, particularly before menopause when blood pressure tends to run lower than in age-matched men, making even moderate elevations less clinically conspicuous. Type 2 diabetes, the leading cause of CKD, is rising in women in midlife in parallel with the metabolic shifts of perimenopause.

The physiology of CKD in women is distinct. Women with CKD progress to end-stage kidney failure at somewhat lower rates than men — a difference that creates a false sense of reassurance — but have higher rates of cardiovascular complication, higher rates of anaemia, and in some analyses, worse quality-of-life outcomes at equivalent eGFR levels. Glomerular diseases, the subset specifically studied in the JAMA trial, include conditions like IgA nephropathy and lupus nephritis that disproportionately affect women.

The standard screen for CKD is a urine albumin:creatinine ratio (uACR) and an estimated glomerular filtration rate (eGFR) from a blood sample. Neither requires fasting. Both are available via a standard GP request on a Medicare-rebated pathology form. Many Australians with CKD have never had either test.

Why the verdict is “maybe” and not “yes”

The evidence from these three trials is genuinely strong. The “maybe” verdict is not about the quality of the evidence — it is about the gap between landmark publication and changed clinical practice in Australia.

Guideline revision in Australia follows a structured process: evidence review by the relevant specialty societies (Nephrology, Cardiology), regulatory consideration for any amended indications, then incorporated guidance for general practice through bodies like the RACGP and NPS MedicineWise. This typically takes one to three years from landmark publication to general practice uptake. That is not bureaucratic indifference. It is the mechanism that ensures new evidence is both real and safely applicable in Australian clinical settings before it becomes standard of care.

This means: the evidence is there, and it is compelling, but the clinical practice change has not yet happened. Knowing this story positions you to have an informed conversation with your GP about whether your kidney medicines are optimised as the evidence evolves — not to self-advocate for a specific prescription based on last week’s press release.

2 cents

Two practical steps if any of this is your terrain.

First: if you have hypertension, type 2 diabetes, a family history of kidney disease, or have never had your kidneys specifically checked — add a kidney function check to your next GP visit. A urine albumin:creatinine ratio and eGFR will establish whether you have CKD, how advanced it is, and whether your current medicines are optimised. Kidney Health Australia has patient-facing resources on CKD if you want context before the appointment.

Second: if you already have a CKD diagnosis, the question “are my current medicines managing both my kidney disease and my cardiovascular risk?” is a reasonable one to raise at your next review. Your GP or nephrologist will be tracking the emerging evidence. You don’t need to bring a journal article — the question itself is enough.

This is general health information and does not constitute individual clinical advice.

Verdict

Verdict: maybe — watch this.

Three landmark trials in NEJM, JAMA, and The Lancet show significant benefit for finerenone across non-diabetic CKD populations. The data is robust; the effect sizes are large; the evidence hierarchy is as strong as it gets. Australian guideline incorporation will take time, as it should. In the meantime, knowing your kidney function status — which a urine albumin:creatinine ratio and eGFR can establish — is the practical move available to everyone right now.